Analysts Offer Predictions for OCUL FY2026 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Ocular Therapeutix in a research note issued on Tuesday, May 6th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will post earnings of ($1.46) per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.

A number of other equities research analysts have also issued reports on OCUL. Needham & Company LLC lowered their target price on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an “outperform” rating for the company. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Ocular Therapeutix Stock Down 1.8 %

Shares of NASDAQ OCUL opened at $7.05 on Wednesday. The stock has a fifty day moving average price of $7.42 and a 200 day moving average price of $8.35. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 12-month low of $4.79 and a 12-month high of $11.78. The company has a market cap of $1.12 billion, a P/E ratio of -5.34 and a beta of 1.51.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds have recently made changes to their positions in the business. Barclays PLC raised its stake in Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock valued at $4,451,000 after acquiring an additional 138,441 shares in the last quarter. Courier Capital LLC acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at $482,000. RoundAngle Advisors LLC bought a new stake in shares of Ocular Therapeutix during the fourth quarter valued at about $1,695,000. SG Americas Securities LLC lifted its holdings in Ocular Therapeutix by 58.7% in the fourth quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company’s stock worth $612,000 after purchasing an additional 26,511 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Ocular Therapeutix by 11.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 3,347 shares during the period. Institutional investors own 59.21% of the company’s stock.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.50% of the stock is currently owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.